Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796804 | PMC |
| http://dx.doi.org/10.1002/prp2.705 | DOI Listing |
Publication Analysis
Top Keywords
candidate medications
8
medications covid-19
8
adverse reactions
8
drug-drug interactions
4
interactions candidate
4
covid-19 treatment
4
treatment overview
4
overview drug-drug
4
drug-drug interaction
4
interaction ddi
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!